• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
【24h】

A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.

机译：非小细胞肺癌中的人源化抗IL-6抗体（ALD518）。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Inflammatory pathways may be an important contributor to morbidity and mortality associated with lung cancer. The oncogene-associated inflammatory microenvironment leads to production of inflammatory cytokines such as IL-6. IL-6 is associated with poor prognosis and correlates with debilitating lung-cancer-related symptoms such as fatigue, thromboembolism, cachexia and anemia. IL-6 has been implicated in resistance of lung cancer to EGF inhibitors. A mAb therapy targeting IL-6 may be an effective treatment for the inflammatory microenvironment in lung cancer. AREAS COVERED: An understanding of the inflammatory pathways involved in lung cancer, including the central role of IL-6, and how inflammation affects the course and treatment of lung cancer. The mAb ALD518, which targets IL-6, and its investigational development and use in advanced NSCLC. Preclinical and Phase I and II studies of ALD518 with a focus on NSCLC. How ALD518 could be used in NSCLC in the future. EXPERT OPINION: IL-6-mediated inflammation may contribute to NSCLC-related morbidity and mortality. In preclinical and Phase I and II trials ALD518 targeting IL-6 appears well tolerated and ameliorates NSCLC-related anemia and cachexia. Other clinical outcomes need further study, and may include effects on overall survival, hypercoagulability associated with lung cancer and decreased resistance to EGF-pathway inhibitors.
机译：引言：炎性途径可能是与肺癌相关的发病率和死亡率的重要因素。与癌基因相关的炎性微环境导致产生炎性细胞因子，例如IL-6。 IL-6与不良预后有关，并与使人衰弱的肺癌相关症状如疲劳，血栓栓塞，恶病质和贫血有关。 IL-6与肺癌对EGF抑制剂的耐药性有关。靶向IL-6的mAb疗法可能是治疗肺癌炎症微环境的有效方法。覆盖的领域：了解与肺癌有关的炎症途径，包括IL-6的核心作用，以及炎症如何影响肺癌的病程和治疗。针对IL-6的mAb ALD518及其在晚期NSCLC中的研究开发和使用。 ALD518的临床前，I和II期研究，重点是NSCLC。将来如何将ALD518用于NSCLC。专家意见：IL-6介导的炎症可能导致NSCLC相关的发病率和死亡率。在临床前，I和II期试验中，靶向IL-6的ALD518耐受性良好，并能缓解NSCLC相关的贫血和恶病质。其他临床结果需要进一步研究，其中可能包括对总体生存，与肺癌相关的高凝性和对EGF途径抑制剂抵抗力下降的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号